Shortage of New RSV Treatment Nirsevimab Amid High Demand

Despite limited supply, healthcare providers prioritize treatment for infants under six months and immunocompromised patients.

New monoclonal antibody treatment, Nirsevimab (trade name Beyfortus), reduces the risk of severe RSV disease by about 80% in infants and toddlers, according to the CDC.
The treatment is in short supply due to unexpectedly high demand, with the existing supply being prioritized for infants at highest risk of severe RSV disease.
RSV-related vaccinations were only approved by the Food and Drug Administration this last fall and are recommended for three demographic groups: pregnant people, infants under eight months old, and toddlers and infants eight to 19 months old who are at high risk and adults ages 60 and older.
RSV is a common respiratory virus that usually causes mild symptoms, but infants, toddlers, older adults and people with compromised immune systems are at risk for severe infection and may need hospitalization.
Despite the shortage, healthcare providers are trying to prioritize the limited supply to infants who are under six months old and immunocompromised patients.